Last i heard from a friend who used to work for Biopatch said their entire FSO and Marketing teams have been eliminated, hearing rumors of restructuring and regional team consolidation with DSM's fighting to keep their jobs while some will be impacted and let go so J&J can show shareholder value. Not really Credo like as they love preaching the Credo. New Leadership team looking to shake thing up within MD&D. Is this even worth it to save few $$$ upfront but lose much more due to issues with supply chain and regulatory concerns with FDA?
There are no replies in this thread yet. Be the first to post a reply below: